Abstract: Cholangiopathies, or biliary diseases, account for a significant proportion of adult and paediatric liver disease. In these pathologies, iterative cycles of damage and repair result in the development of a regenerative microenvironment surrounding the bile ducts, which orchestrates both epithelial proliferation and also biliary fibrosis. Ultimately, fibrosis at the cost of repair results in cholestasis and liver failure, necessitating liver transplantation. Whilst the fibrogenic mechanisms in hepatocellular disease have been widely studied, little is known about the processes that regulate biliary scarring. We sought to determine how the injured biliary epithelium communicates to adjacent stromal cells to regulate scar formation, and to identify therapeutically targetable pathways that could be inhibited to reduce biliary scarring, whilst maintaining the pro--regenerative stroma.
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Using human tissue, bile duct organoids and animal models of biliary disease, we show that non--canonical Wnt signalling is important in initiating biliary scarring. This process is driven by myeloid Wnt5a and acts through epithelial Vangl2, which is upstream of Jnk/cJun signalling. Activation of this pathway drives a pro--fibrotic signalling process which instructs portal fibroblasts to synthesise collagen. Finally, we determine that therapeutic Wnt ligand inhibition reduces biliary scarring, identifying non--canonical Wnt signalling as a novel target for anti--fibrotic therapy in cholestatic biliary disease.
Introduction: Biliary diseases, also known as cholangiopathies, account for approximately one--third
of all adult liver disease and 70% of childhood liver disease. However, compared to their parenchymal counterparts, where hepatoyctes are damaged, the mechanisms that drive the progression of cholangiopathies are unknown and therapeutics to target the formation of scar tissue have not been forthcoming (1) . As a result, for the majority of patients with chronic biliary disease, transplantation is the only curative option (2) .
At the tissue level, biliary disease and regeneration relies on linking the proliferation of biliary epithelial cells (cholangiocytes) with the formation of a regenerative microenvironment that provides both inductive cues to the epithelium but also maintains tissue integrity through scar deposition (3, 4) . How these different cellular components are integrated to form a regenerative hub is unknown.
In many contexts, epithelial regeneration is controlled through activation of the canonical Wnt signalling pathway, which relies on the translocation of β--catenin into the nucleus to drive changes in gene expression (5) (6) (7) (8) (9) . In reality, Wnt ligands are integrated into a much larger network, activating a number of Wnt dependant signalling cascades that function independent of β--catenin (10) (11) (12) .
These so called non--canonical Wnt signalling pathways are highly conserved from Drosophila (13) through to vertebrates (14) and utilise Wnt ligands in combination with a broad range of cell surface receptors, to activate diverse downstream processes (15) . The most widely reported non--canonical Wnt signalling cascades are planar cell polarity (PCP), which regulates activation of cJUN dependant transcription and cytoskeletal rearrangement through Rho and Rock (16) (17) (18) , and Wnt/Ca 2+ signalling, which, though modulation of the cellular Ca 2+ concentration, activates NFAT dependant transcription (19) (20) (21) . Other non--canonical Wnt signalling pathways have also been identified; for example activation of YAP/TAZ signalling though Rho dependant inhibition of Lats1/2, however it remains unclear how broadly applicable these pathways are (22) .
A small number of studies have demonstrated that non--canonical Wnt signalling plays a role in post--natal organ growth (23) (24) (25) and in cancer (26) (27) (28) . These studies have shown that, in the adult, non--canonical Wnt components are involved in the activation of cJun N--terminal kinase (JNK) (17) , regulation of matrix--metalloproteinase--14 (29) , activation of integrin αv (30) and promotion of epithelial polarity (25) . Moreover, a small number of reports have indicated that non--canonical Wnt signalling, through Vangl2, regulates the extra--cellular matrix in vivo (4, 25, 31) . However, it remains unclear what the core function of non--canonical Wnt signalling is in the adult liver.
In this study, we demonstrate that a group of Wnt ligands associated with non--canonical Wnt signalling, particularly Wnt4 and Wnt5a, are up regulated rapidly in a model of biliary disease and these ligands are also highly expressed in patients with primary sclerosing cholangitis (a highly fibrotic biliary disease with limited treatment options). Therapeutic inhibition of the Wnt signalling pathway in this context, through the prevention of Wnt ligand secretion, does not affect the proliferation of biliary cells or the number of regenerating bile ducts. It does, however, reduce the level of fibrosis deposited around these proliferating ducts.
We go on to demonstrate that myeloid Wnt5a regulates this process by activating JNK/cJUN signalling specifically in biliary epithelial cells, promoting their cross talk with portal fibroblasts thereby regulating the capacity of these cells to synthesise collagen and form scar tissue. This study represents, to our knowledge, the first description of how non--canonical Wnt signalling functions to regulate adult tissue scarring by integrating a number of cell types and offers a novel therapeutic target to treat biliary diseases in patients.
Results:
The non--canonical Wnt pathway is activated in biliary disease: Previous studies have shown that canonical Wnt signalling is not activated in the injured bile duct (through lack of nuclear accumulation of β--catenin) (5, 32) , however, canonical pathway activity occurs as bile ducts become malignant and the canonical Wnt signal drives tumour progression (33, 34) . Here we show that in biliary epithelial cells from patients who have undergone transplantation for Primary Sclerosing Cholangitis (PSC), and non--PSC patient livers, β--catenin is detected at the cell membrane but not in the nucleus (figure 1a, left--hand panels), indicating that the canonical Wnt pathway is not active. Primary Sclerosing Cholangitis is diagnosed once it is established and as such it is difficult to ascertain whether JNK--cJUN signalling is activated in response to injury and whether the lack of nuclear β--catenin staining is due to this tissue coming from end--stage disease. The 3,5-- figure 6e) . Notably, PTK7 protein could also be detected on portal fibroblasts, however there was no Vangl2 expressed in these cells and therefore the role of PTK7
here is unclear (supplementary 6g, lower panels). We could not rule out that PTK7 directly receives the Wnt5a signal, thereby conferring the fibrogenic phenotype we have described in the absence of Vangl2.
To determine whether Vangl2--Ptk7 signalling can account for the changes in fibrosis seen following Porcupine--i or myeloid Wnt5a deletion, bile duct organoids were generated from mice containing However, following damage, the levels of PSR and Collagen--1 deposited in the Vangl2 WT are significantly higher than the levels in Vangl2  S464N mutants (figure 5i) . Moreover, the levels of Desmin or Krt19 positive cells do not change between mutant and wild--type animals (figure 5j and 5k), however levels of CTGF do (figure 5l), suggesting that there is an alteration in the capacity of portal fibroblasts to synthesise Collagen--1, rather than a change in the number of fibrogenic cells per se. Therefore, having a mechanism though which the epithelium can regulate the stroma adjacent to it allowing for sufficient co--evolution of the regenerative microenvironment, whilst regulating scar formation, must be a centrally important aspect of tissue repair.
Two previous reports (32, 42) have demonstrated differing effects of myeloid Wnts in mouse models of cholestatic damage. Our data, deleting Wnt5a from myeloid cells, appears to support the conclusions drawn by Okabe et al, who showed that loss of myeloid Wnt production through the loss of Wls resulted in a reduced fibrotic response in DDC model of biliary injury. Furthermore, our data support their speculation, that it is likely to be a Wnt dependant, but β--catenin independent pathway that regulates this biliary repair process in vivo. However, our data does contradict these reports in some aspects, as we fail to see changes in the number of bile ducts formed following Wnt5a deletion. This could be explained by the Wnt ligands, with diverse functions, expressed by macrophages and would explain the Wls phenotype seen by Okabe et al (34, (61) (62) (63) . Similarly, the differences we see between our study and a more chronic TAA model, in which Wls is deleted, can be explained by parenchymal damage secondary to chronic biliary disease (64) . It has previously been shown that Wnt signalling is needed for hepatocyte regeneration (9, 65, 66) following injury, an increase in fibrosis would be expected if loss of myeloid Wnts results in a failure to drive this epithelial repair process in the parenchyma.
Modulating the canonical Wnt signalling pathway has proven difficult in the non--cancerous context, potentially due to the relatively limited amount of Wnt activity that is required in homeostasis (67, 68) . Moreover, off--target effects of canonical Wnt inhibitors have limited the usefulness of this pathway therapeutically. However, recent developments have identified well--tolerated canonical Wnt pathway inhibitors that are being used in a range of oncological indications. We suggest that in the liver, the non--canonical Wnt signalling pathway is activated in biliary disease and that this pathway can be modulated to minimise biliary scarring while maintaining the cellular complexity of the regenerating microenvironment. Given that in many biliary diseases injury occurs in iterative and cyclical patterns, understanding the initiating signals and targeting these could lead to significant patient improvement.
Materials:
Mouse models: All mice were maintained in 12h light/dark cycles and had access to food and water ad libitum in accordance with UK Home Office Regulations. All experiments were performed under license PPL: 70/8150 held by Dr Luke Boulter, mice were euthanised by an escalating dose of CO 2 .
For the DDC mouse model. 6--8--week--old, male CD1 mice were fed 0.1% 5--diethoxycarbonyl--1,4--dihydrocollidine (DDC) in their diet for up to 14 days and provided with normal drinking water. Mice which drop >20% of their bodyweight were given DDC food softened with water. In studies were mice received the Porcupine inhibitor, LGK974 experimental mice were dosed with 5mg/Kg LGK974, twice daily via oral gavage (the vehicle for this was 0.5% methylcellulose and 0.5% Tween--80 in dH2O). Mice were dosed for 48h prior to the administration of DDC to ensure inhibited Wnt ligand production prior to injury. Effectiveness of LGK974 was confirmed through reduction of GS staining adjacent to central veins and is known to be Wnt ligand dependent. 
Human tissue:
RNA isolation and RT--PCR: RNA was isolated from both tissue and organoids using a modified Trizol
Method. Briefly, tissue was homogenized in Trizol and RNA collected from the aqueous phase following chloroform extraction. RNA was precipitated from the aqueous phase using isopropanol.
Precipitated RNA was applied to an RNeasy Mini Spin Column (Qiagen) and the manufacturer's protocol was followed. RNA was suspended in RNAse/DNAse free H2O and quantified using a Nanodrop (Thermofisher). 1ug total RNA was treated with gDNA wipe--out buffer (Qiagen) and reverse transcribed using the Quantitect reverse transcription kit (Qiagen) as per the manufacturer's instructions. For quantitative PCR 10ug total cDNA was used per reaction and was run using FastStart SYBR Green reagent (Roche), cycle conditions were defined by the manufactures protocol. All qRT--PCR was run using a Lightcycler 480--II. All primer sets used in this study were purchased from Qiagen ( Qiagen  QT00126539  bmp4  Qiagen  QT00111174  ccnd1  Qiagen  QT00154595  cd44  Qiagen  QT00173404  ctgf  Qiagen  QT00096131  cyr61  Qiagen  QT00245217  dcn1  Qiagen  QT00131068  dkk1  Qiagen  QT00146307  dvl2  Qiagen  QT00112154  dvl3  Qiagen  QT01079092  egfr  Qiagen  QT00101584  fzd3  Qiagen  QT00147917  fzd6  Qiagen  QT00109998  gas1  Qiagen  QT00253190  igfbp1  Qiagen  QT00114716  lef1  Qiagen  QT00148834  mmp14  Qiagen  QT01064308  mmp3  Qiagen  QT00107751  mmp7  Qiagen  QT00110012 myc  Qiagen  QT00096194  pkcθ  Qiagen  QT00171325  ptk7  Qiagen  QT00144032  rybp  Qiagen  QT00310275  sparc  Qiagen  QT00161721  stat6  Qiagen  QT01042503  tpm  Qiagen  QT00137354  vangl1  Qiagen  QT00494235  vangl2  Qiagen  QT00128422  wnt11  Qiagen  QT00103663  wnt4  Qiagen  QT00104622  wnt5a Qiagen PPR42408A  ctgf  SAbiosciences  PPR46426B  mmp14  SAbiosciences  PPR44815A  mmp3  SAbiosciences  PPR48487B  mmp7  SAbiosciences  PPR44767C  ptk7  SAbiosciences  PPR52923C  sparc  SAbiosciences  PPR53743A  vangl2  SAbiosciences  PPR54102B  wnt5a SAbiosciences PPR50278A
Tissue fixation and Immunohistochemistry: Following euthanasia, livers were flushed through with 20ml physiological saline. Dissected liver lobes were then fixed overnight in 10% neutral buffered formalin in PBS. Following fixation, tissue was dehydrated in 70% ethanol and processed to wax using a tissue processor. 4µM tissue sections were cut and rehydrated through graduated alcohols.
Tissue sections were antigen retrieved as per Table  2 . For DAB staining of antigens, tissue sections were treated with 10% H 2 O 2 washed and then native streptavidin and biotin was blocked using a commercial avidin and biotin blocking kit. Following this, sections were blocked with a universal protein block. Tissue sections were incubated over--night with primary antibodies diluted in antibody diluent. Following washing, biotin conjugated secondary antibodies were incubated with tissue sections as per Table 2 . Sections were further incubated with ABC vectorstain and colour was developed using DAB substrate. For tyramide stained sections, the avidin/biotin step is omitted and HRP conjugated secondary antibodies and Alexa488 or Alexa594 conjugated tyramide was used as per the manufacturer's instructions. For directly conjugated immunofluorescent antibodies, the same protocol was performed, omitting the H 2 O 2 and Avidin/Biotin blocking stage. RNAScope: RNAscope was performed on formalin fixed liver tissue. 4µm sections were used throughout and all RNAScope performed in this study was done by Aquila Histoplex, Edinburgh.
Bile duct isolation:
To isolate bile ducts from both uninjured and injured livers dissected liver was chopped into 5mm 3 pieces and digested in DMEM/F12 media containing Collagenase--IV (Roche) and Western blotting: Isolated bile ducts or organoids were lysed in RIPA buffer containing phosphatase (ThermoFisher) and protease (MiniComplete, Roche) inhibitors. Protein quantification was determined using Pierce BCA reagent (Pierce) and quantified using a nanodrop. The standard curve for protein quantification was derived from the BCA reagent handbook using Albumin standards provided. 20ug total protein was loaded onto a 4--12% NuPage Bis--Tris gel (ThermoFisher). Prior to running, proteins were reduced with NuPage LDS sample buffer (4x) and NuPage Sample Reducing Agent (10x). All gels were run using NuPage MOPS SDS Running buffer containing NuPage Antioxident. Proteins were transferred onto PVDF membrane (Amersham) using NuPage Transfer
Buffer. Following transfer, membranes were blocked in either 5% BSA (Sigma Aldrich) in TBST or 5% dried milk (Marvel) in TBST. Membranes were incubated with primary antibodies ( 
